Recently, I posted when the March of Dimes took its’ position on Ther-Rx and the availability of progesterone therapy to women in need of it.
Here is an update on the ongoing efforts of the March of Dimes concerning this important issue.
“MOD responds to Ther-Rx
In the past few weeks, there has been a torrent of concern over the availability of progesterone therapy for women hoping to prevent premature birth. We have held discussions with physician groups, various organizations and the manufacturer of the drug. Ther-Rx Corporation’s handling of the launch of Makena, and the initial list price, were extremely disappointing and unacceptable to the March of Dimes and the families we represent. While Ther-Rx Corporation’s decision yesterday to reduce the list price of Makena to $690 and to expand patient financial assistance are steps in the right direction toward making an FDA-approved progesterone therapy product more widely available, it’s not enough. The March of Dimes has decided to exercise our right to terminate our current contract and sever all professional relationships with Ther-Rx.
The March of Dimes will continue to explore all options for ensuring access to progesterone therapy for all medically eligible women. Access for women to treatment to prevent premature birth is and always has been our paramount concern. We hope that the controversy surrounding Makena has helped raise awareness that progesterone therapy is a safe and effective treatment for prevention of preterm birth and that more obstetricians will consider it for appropriate patients.
Tags: 17p, KV Pharmaceuticals, Makena, pregesterone therapy, premature birth, Ther-Rx
Related posts: March of Dimes takes a stand...